Screener
ADMA Biologics ADMA Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: ADMA Biologics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:16 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001140361-26-019336
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| JPM revolving facility proceeds | 125,000 | - |
| Taxes paid on vested restricted stock units | (5,058) | (7,228) |
| Net proceeds from the exercise of stock options | 588 | 101 |
| Acquisition of treasury stock | (130,191) | - |
| Net cash used in financing activities | (10,130) | (7,127) |
| Net increase (decrease) in cash and cash equivalents | 50,523 | (31,522) |
| Cash and cash equivalents - beginning of period | 87,630 | 103,147 |
| Cash and cash equivalents - end of period | $$138,153 | 71,625 |
Item 1.
FAQ
- What is ADMA Biologics's net change in cash?
- ADMA Biologics (ADMA) reported net change in cash of $50.52M in Q1 2026.
- How has ADMA Biologics's net change in cash changed year-over-year?
- ADMA Biologics's net change in cash increased by 260.3% year-over-year, from -$31.52M to $50.52M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about ADMA Biologics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude